VPC
URGN icon

Vestal Point Capital’s UroGen Pharma URGN Stock Holding History

Vestal Point Capital’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-139,079
Closed -$2.5M – 93
2026
Q1 		$2.5M Buy
+139,079
New +$2.79M 0.07% 83
2025
Q2 		– Sell
-2,152,957
Closed -$23.8M – 84
2025
Q1 		$23.8M Buy
2,152,957
+522,957
+32% +$5.58M 1.7% 20
2024
Q4 		$17.4M Buy
1,630,000
+1,230,000
+308% +$14.7M 1.03% 33
2024
Q3 		$5.08M Buy
+400,000
New +$5.94M 0.39% 48

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vestal Point Capital's URGN Position: Q2 2026 in Review

Vestal Point Capital sold out of UroGen Pharma (URGN) in Q2 2026, closing a stake of 139,079 shares — an estimated $2.5M sold.

Vestal Point Capital first reported a position in URGN in Q3 2024 and held it in 4 quarters. The position peaked at $23.8M in Q1 2025. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • Vestal Point Capital reported no remaining UroGen Pharma position as of Q2 2026 after selling out during the quarter.
  • Vestal Point Capital sold 139,079 UroGen Pharma shares in Q2 2026, an estimated $2.5M.
  • Vestal Point Capital first reported a position in UroGen Pharma in Q3 2024 and held it in 4 quarters.
  • Vestal Point Capital's UroGen Pharma position peaked at $23.8M in Q1 2025.
  • 189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.